Exscientia Announces Second Molecule Created Using AI From Sumitomo Dainippon Pharma Collaboration to Enter Phase 1 Clinical Trial
Exscientia Ltd. (Headquarters: Oxford, UK; CEO: Andrew Hopkins) is pleased to acknowledge that Sumitomo Dainippon Pharma Co., Ltd. (Head office: Osaka, Japan, Representative Director, President and CEO: Hiroshi Nomura) has announced that they will initiate a Phase 1 clinical study of DSP-0038 in the United States for the treatment of Alzheimer’s disease psychosis.
DSP-0038 is the third molecule created using Exscientia’s Artificial Intelligence (AI) technologies to enter clinical trials. The two earlier compounds are DSP-1181, announced in 2020 together with Sumitomo Dainippon Pharma to treat obsessive-compulsive disorder, and Exscientia’s immuno-oncology agent, EXS-21546, announced earlier this year.
Joint research between Exscientia and Sumitomo Dainippon Pharma designed DSP-0038 to be a single small molecule that exhibits high potency as an antagonist for the 5-HT2A receptor and agonist for the 5-HT1A receptor, whilst selectively avoiding similar receptors and unwanted targets, such as the dopamine D2 receptor. Selective dual targeting is a major challenge for conventional drug discovery, and psychiatric indications also require exceptional selectivity to avoid off-target effects. The successful design of DSP-0038 demonstrates opportunities to design selective molecules with dual activity.
DSP-0038 will be assessed for improved antipsychotic effects associated with Alzheimer’s disease psychosis, as well as improvements in behavioural and psychological symptoms of dementia which include agitation, aggression, anxiety, and depression.
Toru Kimura, Representative Director, Executive Vice President and Chief Scientific Officer of Sumitomo Dainippon Pharma, said: "We have been impressed by the outstanding productivity of Exscientia's AI technologies. The combination of Exscientia’s AI with our company’s deep experience in monoamine GPCR drug discovery has now led to two molecules reaching our clinical pipeline from this collaboration.”
Andrew Hopkins, CEO of Exscientia, said: "This is further validation that our AI platform can turn complex biological challenges into high-quality clinical candidates quickly. To have what we believe to be the world’s first three clinical molecules created using AI arising from our own platform – two with Sumitomo Dainippon Pharma - is a wonderful achievement. We hope that through the creation of DSP-0038 improved treatments for Alzheimer’s disease psychosis will be realized."
About Exscientia
Exscientia is an AI-driven pharmatech company committed to discovering and designing the best possible medicines in the fastest and most effective manner. Exscientia is the first company to progress AI-designed small molecules into the clinical setting and repeatedly demonstrate the ability of AI to transform how drugs are created. Exscientia’s AI platform has now designed two drugs that are in Phase 1 human clinical trials.
Drug design is precision engineering at the molecular scale. Exscientia has built dedicated AI systems that efficiently learn from the widest range of data and consistently reapply enhanced knowledge through iterations of design. Because Exscientia’s AI platform learns more effectively and rapidly than human-led efforts alone, candidate molecules satisfying complex therapeutic requirements are created with revolutionary efficiency. Exscientia believes that designing better drugs, faster, will allow the best ideas of science to rapidly become the best medicines for patients.
Exscientia has offices in Oxford, Miami, Osaka and Dundee. For more information visit us on www.exscientia.ai or follow us on Twitter @exscientiaAI.
About Sumitomo Dainippon Pharma Co., Ltd.
Sumitomo Dainippon Pharma defines its corporate mission as "To broadly contribute to society through value creation based on innovative research and development activities for the betterment of healthcare and fuller lives of people worldwide." By pouring all our efforts into the research and development of new drugs, we aim to realize our corporate mission and provide innovative and effective pharmaceutical
solutions to people not only in Japan but also around the world. Sumitomo Dainippon Pharma's goal is to create innovative pharmaceutical products in the focus research areas of Psychiatry & Neurology, Oncology and Regenerative Medicine/Cell Therapy. For further details, visit https://www.ds-pharma.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210513005059/en/
Contact information
Enquiries:
Edelman
Anitra Sprauten
P: +44 (0)7896 859386
Anitra.Sprauten@edelman.com
Stephanie Crisp
P: +44 (0)7583 003417
Stephanie.Crisp@edelman.com
For Exscientia
Mark Swindells: contact@exscientia.ai
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
British Arab Commercial Bank Partners With Volante Technologies to Modernize Payments Infrastructure With PaaS22.10.2025 16:38:00 EEST | Press release
Volante Technologies, the global leader in Payments as a Service (PaaS), today announced a new partnership with British Arab Commercial Bank (BACB), to modernize the bank’s payment processing infrastructure and replace legacy systems with a cloud-native platform. BACB will use Volante’s PaaS solution to automate and streamline the entirety of its payments volumes across multiple payment schemes, including SWIFT MT/ISO 20022, CHAPS, Faster Payments, BACS, and internal transfers. Volante’s solution enables BACB to move beyond legacy systems and manual processes, empowering the bank to raise straight-through processing rates and continue to provide a first-class service to its customers. BACB is an international wholesale bank, with $4.4 billion in assets, who provide a range of trade solutions to clients trading in and out of developing markets, across Africa and the Middle East. The bank sought a strategic partner with both technological capabilities and cultural alignment to modernize
Andersen Consulting Adds Breadth to Digital Transformation Capabilities with MOYO22.10.2025 16:30:00 EEST | Press release
Andersen Consulting continues to expand its business and technology transformation capabilities through a Collaboration Agreement with MOYO, a digital consultancy delivering integrated solutions across strategy, data, technology, engineering, and talent development. Founded in 2007 by Managing Director Pierre le Roux, MOYO combines consulting, technology, and human capital services to help a diverse client base—from startups to large enterprises across the financial services, mining, and retail industries—implement scalable systems, optimize processes, and deliver purpose-built solutions that capture new opportunities in the digital economy. “At MOYO, we believe digital transformation only succeeds when solutions are built with deep empathy and a clear understanding of the people behind the business,” Pierre said. “Our collaboration with Andersen Consulting reflects that same commitment to meaningful, long-term change.” “MOYO’s blend of technical expertise and practical innovation make
Qualcomm Schedules Fourth Quarter and Fiscal 2025 Earnings Release and Conference Call22.10.2025 16:00:00 EEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced that it will publish the Company’s financial results for its fourth quarter and fiscal 2025 on Wednesday, November 5, 2025, after the close of the market on the Company’s Investor Relations website, at https://investor.qualcomm.com/financial-information. The earnings release will also be furnished to the Securities and Exchange Commission (SEC) on a Form 8-K, which will be available on the SEC website at http://www.sec.gov. Qualcomm will host a conference call to discuss its fourth quarter and fiscal 2025 results which will be broadcast live on November 5, 2025, beginning at 1:45 p.m. Pacific Time (PT) at https://investor.qualcomm.com/news-events/investor-events/default.aspx. An audio replay will be available at https://investor.qualcomm.com/news-events/investor-events/default.aspx and via telephone following the live call for 30 days thereafter. To listen to the replay via telephone, U.S. callers may dial (877) 660-6853 and internat
XPRIZE and Avanci Launch Partnership to Provide Innovators with IP and Licensing Expertise22.10.2025 16:00:00 EEST | Press release
XPRIZE, the world’s leader in designing and operating incentive competitions to solve humanity’s greatest challenges, and Avanci, the independent global leader in one-stop IP licensing platforms, today announced a partnership to empower XPRIZE innovators. For more than three decades, XPRIZE competitions have ignited bold solutions that ripple far beyond the competition itself to transform industries, inspire new technologies, and build an extraordinary global ecosystem of innovators dedicated to problem solving. This partnership with Avanci ensures that XPRIZE teams and alumni have access to the expertise and resources they need to protect, scale, and amplify their impact in the real world through access to Avanci’s expertise and experience in intellectual property (IP) protection and licensing. Tailored support from Avanci will help those entrepreneurs protect their breakthrough innovations, navigate complex licensing landscapes, and position them for greater success. “The impact of o
Cyclic Materials and VACUUMSCHMELZE Expand Partnership to Recycle Rare Earth Magnet Manufacturing Waste in the U.S.22.10.2025 16:00:00 EEST | Press release
Cyclic Materials, the advanced recycling company creating a circular supply chain for rare earth elements (REEs) and other critical materials, today announced an expansion of its partnership with VACUUMSCHMELZE (VAC), a leading developer of magnetic materials and solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251022335302/en/ The companies have signed a 10-year exclusive agreement for recycling 100 percent of the magnet production byproducts (i.e. swarf) that will be produced at VAC's impressive new manufacturing facility in Sumter, South Carolina scheduled to begin operations at the end of 2025. This extended partnership builds on the 2024 agreement between both companies that ensures efficient recycling of critical materials used in high-performance permanent magnets. "At Cyclic Materials, our mission is to recover critical materials from permanent magnets that can be put back into the magnet supply chain to red
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom